Eliminating creatine kinase–myocardial band testing in suspected acute coronary syndrome: A value-based quality improvement

Matthew D. Alvin, Allan S Jaffe, Roy C. Ziegelstein, Jeffrey C. Trost

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Cardiac biomarker testing is estimated to occur in nearly 30 million emergency department visits nationwide each year in the United States. The American College of Cardiology/ European Society of Cardiology indicate that cardiac troponin is the biomarker of choice owing to its nearly absolute myocardial tissue specificity and high clinical sensitivity for myocardial injury. Multiple academic medical centers have implemented interventions to eliminate the routine ordering of creatine kinase–myocardial band tests, with published patient safety outcomes data; however, creatine kinase–myocardial band testing is still ordered in many hospitals and emergency departments. Eliminating a simple laboratory test that provides no incremental value to patient care can lead to millions of health care dollars saved without adversely affecting patient care quality, and in this case potentially improving patient care.

Original languageEnglish (US)
Pages (from-to)1508-1512
Number of pages5
JournalJAMA Internal Medicine
Volume177
Issue number10
DOIs
StatePublished - Oct 1 2017

Fingerprint

Creatine
Acute Coronary Syndrome
Quality Improvement
Patient Care
Hospital Emergency Service
Biomarkers
Organ Specificity
Troponin
Hospital Departments
Patient Safety
Delivery of Health Care
Wounds and Injuries

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Eliminating creatine kinase–myocardial band testing in suspected acute coronary syndrome : A value-based quality improvement. / Alvin, Matthew D.; Jaffe, Allan S; Ziegelstein, Roy C.; Trost, Jeffrey C.

In: JAMA Internal Medicine, Vol. 177, No. 10, 01.10.2017, p. 1508-1512.

Research output: Contribution to journalArticle

@article{303780561e2c4046a7146736a3223e60,
title = "Eliminating creatine kinase–myocardial band testing in suspected acute coronary syndrome: A value-based quality improvement",
abstract = "Cardiac biomarker testing is estimated to occur in nearly 30 million emergency department visits nationwide each year in the United States. The American College of Cardiology/ European Society of Cardiology indicate that cardiac troponin is the biomarker of choice owing to its nearly absolute myocardial tissue specificity and high clinical sensitivity for myocardial injury. Multiple academic medical centers have implemented interventions to eliminate the routine ordering of creatine kinase–myocardial band tests, with published patient safety outcomes data; however, creatine kinase–myocardial band testing is still ordered in many hospitals and emergency departments. Eliminating a simple laboratory test that provides no incremental value to patient care can lead to millions of health care dollars saved without adversely affecting patient care quality, and in this case potentially improving patient care.",
author = "Alvin, {Matthew D.} and Jaffe, {Allan S} and Ziegelstein, {Roy C.} and Trost, {Jeffrey C.}",
year = "2017",
month = "10",
day = "1",
doi = "10.1001/jamainternmed.2017.3597",
language = "English (US)",
volume = "177",
pages = "1508--1512",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Eliminating creatine kinase–myocardial band testing in suspected acute coronary syndrome

T2 - A value-based quality improvement

AU - Alvin, Matthew D.

AU - Jaffe, Allan S

AU - Ziegelstein, Roy C.

AU - Trost, Jeffrey C.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Cardiac biomarker testing is estimated to occur in nearly 30 million emergency department visits nationwide each year in the United States. The American College of Cardiology/ European Society of Cardiology indicate that cardiac troponin is the biomarker of choice owing to its nearly absolute myocardial tissue specificity and high clinical sensitivity for myocardial injury. Multiple academic medical centers have implemented interventions to eliminate the routine ordering of creatine kinase–myocardial band tests, with published patient safety outcomes data; however, creatine kinase–myocardial band testing is still ordered in many hospitals and emergency departments. Eliminating a simple laboratory test that provides no incremental value to patient care can lead to millions of health care dollars saved without adversely affecting patient care quality, and in this case potentially improving patient care.

AB - Cardiac biomarker testing is estimated to occur in nearly 30 million emergency department visits nationwide each year in the United States. The American College of Cardiology/ European Society of Cardiology indicate that cardiac troponin is the biomarker of choice owing to its nearly absolute myocardial tissue specificity and high clinical sensitivity for myocardial injury. Multiple academic medical centers have implemented interventions to eliminate the routine ordering of creatine kinase–myocardial band tests, with published patient safety outcomes data; however, creatine kinase–myocardial band testing is still ordered in many hospitals and emergency departments. Eliminating a simple laboratory test that provides no incremental value to patient care can lead to millions of health care dollars saved without adversely affecting patient care quality, and in this case potentially improving patient care.

UR - http://www.scopus.com/inward/record.url?scp=85030977750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030977750&partnerID=8YFLogxK

U2 - 10.1001/jamainternmed.2017.3597

DO - 10.1001/jamainternmed.2017.3597

M3 - Article

C2 - 28806444

AN - SCOPUS:85030977750

VL - 177

SP - 1508

EP - 1512

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 10

ER -